Archon Biosciences
Facts
- HQ
- Seattle, Washington, US
- Sectors
- Biotechnology Research
- Founded
- 2023 Seattle business license
- Type
- Corporation Seattle business license
- Employees
- 26
- Registered name
- Archon Biosciences Inc Seattle business license
- Stage
- Seed
Fred Hutch-Led Synthesize Bio Raises $10M to Accelerate Drug Discovery Using AI Gene Expression Model
Seattle-based Synthesize Bio, led by Fred Hutchinson Cancer Center researchers, raised $10 million from Madrona to accelerate drug discovery using their AI model GEM-1, which predicts gene expression outcomes with lab-level accuracy. The startup aims to reduce drug development time and costs by simulating hypothetical lab experiments with generative genomics.
Archon's Jamie Lazarovits on Unlocking the Full Power of Antibodies With AI
What does it take to move from cutting-edge academic research to launching a biotech company that could transform medicine? In this week's episode of Founded & Funded, Madrona Partner Chris Picardo sat down with Jamie Lazarovitz, CEO and co-founder of Archon Biosciences, to uncover the story behind their groundbreaking protein-based biologics and their unique Antibody Cages (AbCs). From bootstrapping deep tech investments as a student to navigating the challenges of commercializing revolutionary science, Jamie shares the pivotal moments, tough decisions, and key lessons that led to Archon's creation. This isn't just a story for biotech enthusiasts — every founder can…
Archon Biosciences Raises $20M to Develop AI-Optimized Antibody Cages for Disease Treatment
Archon Biosciences has emerged from stealth with $20 million in seed funding led by Madrona Ventures to develop Antibody Cages, computationally designed protein structures optimized with AI for treating cancer and other diseases. The technology builds on protein design research linked to a recent Nobel Prize awarded to University of Washington biochemist David Baker.
People
-
George Ueda Founder, Co-Founder and CTO
-
Chris Picardo Board Member
